기관지확장증 시장 : 기회 평가와 예측 - 최신 정보

This report covers the 8MM (US, France, Germany, Italy, Spain, UK, Japan, China) and provides an Excel-based forecast model for the bronchiectasis market through 2033. Report deliverables include a PowerPoint report and an Excel-based forecast model.

Bronchiectasis, which has been given diagnostic code of J47.9 from the International Classification of Diseases, Tenth Edition (ICD-10), is defined by damage to the bronchi, causing abnormal dilation and scarring. The airways become inflamed with thick mucus that is difficult to clear, which build-up creates an environment for bacterial growth; uncontrolled bacterial growth leads to frequent infections. The cycle of repeated infections can in turn cause further damage to the airways. Bronchiectasis can occur throughout the lung or in a single section of lung.

Bronchiectasis is split into two main types: cystic fibrosis (CF), a genetically inherited disorder affecting the lungs, and non-CF bronchiectasis. Individuals who have CF can have lung symptoms similar to those of bronchiectasis, but for the purposes of this report, only non-CF bronchiectasis will be discussed. Some patients are symptom-free in everyday life and become clinically conspicuous only during exacerbations. Symptoms include excessive coughing (can be dry or productive, although productive cough is more common, especially in more severe/advanced disease), sputum production, recurrent chest infections, malaise, chest discomfort, hemoptysis, and weight loss.

The forecast model covers the market forecast for bronchiectasis treatments. The base year of this model is 2023, and the forecast period is 2023-2033. The bronchiectasis market in the 8MM was valued at $1.5 billion in 2023. The market is projected to grow at a compound annual growth rate (CAGR) of 9.8%, reaching $3.7 billion by 2033, with pipeline agents adding over $1.8 billion in sales.

Scope

• Overview of bronchiectasis, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized bronchiectasis treatment market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the bronchiectasis therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for bronchiectasis treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
• Analysis of the current and future market competition in the global bronchiectasis therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
• Develop business strategies by understanding the trends shaping and driving the eight-market bronchiectasis therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the eight-market bronchiectasis market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track drug sales in the eight-market bronchiectasis therapeutics market from 2023-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1. Preface

• 1.1. Contents
• 1.2. Abbreviations
• 1.3. Summary of Updates
• 1.4. Related Reports

2. Executive Summary

3. Disease Overview

• 3.1. Overview of Bronchiectasis
• 3.2. Bronchiectasis SWOT Analysis
• 3.3. Pathophysiology of Bronchiectasis
• 3.4. Classification of Bronchiectasis

4. Epidemiology

• 4.1. Total Prevalent Cases of Bronchiectasis, Both Sexes, Ages >=18 Years, 2023-33
• 4.2. Total Prevalent Cases of Bronchiectasis, Both Sexes, Ages >=18 Years, 2023-33
• 4.3. Age-Specific Trends in Diagnosed Prevalent Cases of Bronchiectasis, Both Sexes, 2023
• 4.4. Sex-Specific Diagnosed Prevalent Cases of Bronchiectasis, Both Sexes, Ages >=18 Years, 2023
• 4.5. Diagnosed Prevalent Cases of Bronchiectasis By Severity, Both Sexes, Ages >=18 Years, 2023
• 4.6. Sources and Methodology for Diagnosed Prevalence of Bronchiectasis

5. Current Treatment Options

• 5.1. Treatment Paradigm
• 5.2. Marketed Products
• 5.3. Product Profile: Antibiotics (Oral, IV, Inhaled)
• 5.4. Product Profile: Bronchitol
• 5.5. Product Profile: Hypertonic Saline
• 5.6. Product Profile: Mucolytics
• 5.7. Product Profile: Bronchodilators
• 5.8. Product Profile: Asthma Biologics
• 5.9. Product Profile: Inhaled Steroids
• 5.10. Bronchiectasis Patient Flow Across the 8MM in 2023

6. Unmet Needs and Opportunities

• 6.1. Unmet Needs in Bronchiectasis
• 6.2. Increased Awareness and Education
• 6.3. Improved Diagnostic Methods
• 6.4. Lack of Approved Therapies
• 6.5. Targets for Improved Therapies

7. R&D Strategies

• 7.1. Trends in Clinical Trial Design in Bronchiectasis
• 7.2. Trends in Deal-Making in Bronchiectasis

8. Pipeline Assessment

• 8.1. Bronchiectasis Pipeline Overview
• 8.2. Late-Stage Pipeline Agents for Bronchiectasis
• 8.3. Product Profile: Insmed's Brensocatib
• 8.4. Product Profile: Haisco's HSK31858
• 8.5. Boehringer Ingelheim's BI 1291583
• 8.6. Bronchiectasis: Clinical Trials - Phase II and Phase III Overview

9. Market Outlook

• 9.1. Bronchiectasis Market Forecast
• 9.2. Market Drivers and Barriers

10. Appendix

• 10.1. Primary Research: KOL Information
• 10.2. Bibliography
• 10.3. About the Authors

11. Contact Us